mTOR Pathway and mTOR Inhibitors in Cancer Therapy (Record no. 110785)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03393nam a22004935i 4500 |
| 001 - CONTROL NUMBER | |
| control field | 978-1-60327-271-1 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20140220084512.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 100722s2010 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781603272711 |
| -- | 978-1-60327-271-1 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/978-1-60327-271-1 |
| Source of number or code | doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC261-271 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MJCL |
| Source | bicssc |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED062000 |
| Source | bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 614.5999 |
| Edition number | 23 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Polunovsky, Vitaly A. |
| Relator term | editor. |
| 245 10 - TITLE STATEMENT | |
| Title | mTOR Pathway and mTOR Inhibitors in Cancer Therapy |
| Medium | [electronic resource] / |
| Statement of responsibility, etc | edited by Vitaly A. Polunovsky, Peter J. Houghton. |
| 264 #1 - | |
| -- | Totowa, NJ : |
| -- | Humana Press : |
| -- | Imprint: Humana Press, |
| -- | 2010. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | XII, 304 p. |
| Other physical details | online resource. |
| 336 ## - | |
| -- | text |
| -- | txt |
| -- | rdacontent |
| 337 ## - | |
| -- | computer |
| -- | c |
| -- | rdamedia |
| 338 ## - | |
| -- | online resource |
| -- | cr |
| -- | rdacarrier |
| 347 ## - | |
| -- | text file |
| -- | |
| -- | rda |
| 490 1# - SERIES STATEMENT | |
| Series statement | Cancer Drug Discovery and Development |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | mTORC1: A Signaling Integration Node Involved in Cell Growth -- The Regulation of the IGF-1/mTOR Pathway by the p53 Tumor Suppressor Gene Functions -- mTOR Signaling in Angiogenesis -- mTORC1 Signaling and Hypoxia -- mTOR Signaling in Glioblastoma: Lessons Learned from Bench to Bedside -- mTOR and Cancer Therapy: General Principles -- mTOR and Cancer Therapy: Clinical Development and Novel Prospects -- Drug Combinations as a Therapeutic Approach for mTORC1 Inhibitors in Human Cancer -- Downstream Targets of mTORC1 -- Downstream of mTOR: Translational Control of Cancer -- Genome-Wide Analysis of Translational Control -- Translational Control of Cancer: Implications for Targeted Therapy -- Downstream from mTOR: Therapeutic Approaches to Targeting the eIF4F Translation Initiation Complex. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | mTOR Pathway and mTOR Inhibitors in Cancer Therapy provides an up-to-date survey of the rapidly advancing field of cancer therapy. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment – targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. In this work, experts in TOR signaling have contributed in two thematic areas: mTOR Signaling and Cancer Therapy (chapters 1 - 8) and Therapeutic Targeting Downstream of mTOR (chapter 9 – 13). All chapters of mTOR Pathway and mTOR Inhibitors in Cancer Therapy are completely new or have been extensively updated by their authors; and we are indebted to all authors who have exemplified the links between these 2 thematic areas. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Medicine. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Oncology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Toxicology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Cytology. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Biomedicine. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Cancer Research. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Cell Biology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmacology/Toxicology. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Houghton, Peter J. |
| Relator term | editor. |
| 710 2# - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY | |
| Title | Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Display text | Printed edition: |
| International Standard Book Number | 9781603272704 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Cancer Drug Discovery and Development |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | http://dx.doi.org/10.1007/978-1-60327-271-1 |
| 912 ## - | |
| -- | ZDB-2-SME |
No items available.